Toyota|$17.71 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.56 (¥4,242)+1.00%▲ (in JPY terms)
SoftBank|$24.31 (¥3,883)+0.73%▲ (in JPY terms)
MUFG|$21.91 (¥3,499)-0.09%▼ (in JPY terms)
Keyence|$471.90 (¥75,370)-0.46%▼ (in JPY terms)
Nintendo|$53.01 (¥8,466)+1.13%▲ (in JPY terms)
NTT|$1.04 (¥166)+2.53%▲ (in JPY terms)
Takeda|$42.56 (¥6,798)+1.87%▲ (in JPY terms)
Tokyo Electron|$59.32 (¥9,475)+2.19%▲ (in JPY terms)
Recruit|$104.00 (¥16,610)-6.18%▼ (in JPY terms)
ITOCHU|$15.07 (¥2,408)+1.39%▲ (in JPY terms)
Honda|$11.29 (¥1,803)+1.92%▲ (in JPY terms)
Shin-Etsu|$36.81 (¥5,879)+2.98%▲ (in JPY terms)
Tokio Marine|$3.70 (¥591)-0.15%▼ (in JPY terms)
Fast Retailing|$503.02 (¥80,340)-0.17%▼ (in JPY terms)
Toyota|$17.71 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.56 (¥4,242)+1.00%▲ (in JPY terms)
SoftBank|$24.31 (¥3,883)+0.73%▲ (in JPY terms)
MUFG|$21.91 (¥3,499)-0.09%▼ (in JPY terms)
Keyence|$471.90 (¥75,370)-0.46%▼ (in JPY terms)
Nintendo|$53.01 (¥8,466)+1.13%▲ (in JPY terms)
NTT|$1.04 (¥166)+2.53%▲ (in JPY terms)
Takeda|$42.56 (¥6,798)+1.87%▲ (in JPY terms)
Tokyo Electron|$59.32 (¥9,475)+2.19%▲ (in JPY terms)
Recruit|$104.00 (¥16,610)-6.18%▼ (in JPY terms)
ITOCHU|$15.07 (¥2,408)+1.39%▲ (in JPY terms)
Honda|$11.29 (¥1,803)+1.92%▲ (in JPY terms)
Shin-Etsu|$36.81 (¥5,879)+2.98%▲ (in JPY terms)
Tokio Marine|$3.70 (¥591)-0.15%▼ (in JPY terms)
Fast Retailing|$503.02 (¥80,340)-0.17%▼ (in JPY terms)

2026-09-14 Otsuka Holdings Co.,Ltd. “In the Phase III REZILIENT3 trial for first-line treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations, the combination of diparereltinib and chemotherapy extended the median progression-free survival by 6 months.”

2026-09-14 Otsuka Holdings Co.,Ltd. “In the Phase III REZILIENT3 trial for first-line treatment of non-s … 続きを読む

2026-09-14 DAIICHI SANKYO COMPANY,LIMITED “The latest data from the Phase 3 clinical trial of trastuzumab deruxtecan (T-DXd/DS-8201) for first-line treatment of non-small cell lung cancer with HER2 gene mutations, presented at the World Conference on Lung Cancer (WCLC 2026), will be displayed in a new window as a PDF file (282.8KB).”

2026-09-14 DAIICHI SANKYO COMPANY,LIMITED “The latest data from the Phase 3 clinical trial of trastuzuma … 続きを読む